Etonogestrel contraceptive implant
|Etonogestrel contraceptive implant|
|Birth control type||Hormonal
1998 Indonesia2008, over 61 countries.
|Failure rates (first year)|
|Duration effect||3 years (4 years off-label)|
|User reminders||Requires removal after the 3–4 years|
|Advantages and disadvantages|
|Weight||May cause weight gain|
|Period disadvantages||May cause irregular or prolonged bleeding|
|Period advantages||Minimizes pain. 20% of women will stop having their period.|
Etonogestrel contraceptive implant, sold under the brandnames Nexplanon and Implanon, is a single-rod subdermal contraceptive implant made by Merck & Co. that is inserted just under the skin of a woman's upper arm and contains etonogestrel. Nexplanon/Implanon are a type of long-acting reversible contraception, the most effective form of birth control. Nexplanon and Implanon NXT are essentially identical to Implanon except Nexplanon and Implanon NXT have 15 mg of barium sulphate added to the core, so it is detectable by x-ray. Nexplanon / Implanon NXT also has a pre-loaded applicator for easier insertion. Implanon was first approved for use in Indonesia in 1998, then approved for use in the United States in 2006. Subdermal contraceptive implants are now used by 11 million women around the world and approved for use in over 60 countries as of 2003.
Nexplanon and Implanon are a type of long-acting reversible contraception, which has been shown to be the most effective form of birth control available. The failure rate of Implanon is .05% for both perfect use and typical use because the method requires no user action after insertion. Prospective follow-up studies of Implanon, which include over 2,467 women-years of exposure, have found no pregnancies. Other studies have found some failures with this method, some attributed to failures of the method itself and others to improper placement, drug interactions, or conception prior to method insertion.
In comparison, tubal sterilization has a failure rate of 0.5% and IUDs have a failure rate of 0.2–0.8%. These statistics suggest that Implanon and Nexplanon are almost ten times more effective at preventing pregnancy than tubal sterilization. Also, tubal sterilization is permanent, whereas the subdermal implant is completely reversible, required to be replaced every three years.
Irregular bleeding and spotting may occur: Many women will experience some type of irregular, unpredictable, prolonged, frequent, or infrequent bleeding when using Nexplanon or Implanon. Some women also experience amenorrhea. For some women, prolonged bleeding will decline after the first three months of use. However, other women may experience this bleeding pattern through all three years of use. While these patterns are not dangerous, they are the most common reason that women give for discontinuing the use of the implant. After removal, bleeding patterns return to previous patterns in most women.
Insertion Complications: Some minor side effects such as bruising, skin irritation, or pain around the insertion site are common. However, there are some rare complications that can occur, such as infection or expulsion. In some cases, a serious complication occurs when the provider fails to insert, and the rod is left in the inserter. An Australian study reported 84 pregnancies as a result of such failure.
Migration: Although very rare, the rod can sometimes move slightly within the arm. This can make removal more difficult. It is possible that insertion of an Implanon or Nexplanon in the same site as a previous implant increases the likelihood of migration. Implanon rods can be located only through high-frequency ultrasound or magnetic resonance imaging (MRI). Nexplanon can be located using traditional X-ray or CT-scan because of the inclusion of barium sulphate.
Possible weight gain: Some women may experience slight weight gain when using the implant. However, current studies are not conclusive because they do not compare the weight of women using Implanon/Nexplanon with a control group of women not using the implant. The average increase in body weight in studies was less than 5 pounds (2,25 kg) over 2 years.
Drug interactions: It is possible that the implant has similar drug interactions as combined oral contraceptives. However, drug interactions with Implanon/Nexplanon have not been systematically studied.
Pregnancy: it is recommended that Implanon or Nexplanon be removed if a pregnancy does occur. However, there is no evidence to suggest that the implant has a negative effect on pregnancy or a developing fetus.
Acne: Acne has been self-reported to be a side effect of Implanon, and is listed as a side effect by the FDA. However, a study of Implanon users found that a majority of users with acne before their insertion reported that their acne had decreased, and only 16% of those who did not have acne before insertion developed acne.
Other possible symptoms: Other symptoms that have been reported in clinical trials of Implanon or Nexplanon include headache, emotional lability, abdominal pain, loss of libido, and vaginal dryness. However, there have been no studies that conclusively determine that these symptoms are caused by the implant.
- Are, or think they are, pregnant
- Are allergic to etonogestrel
- Have a history of breast cancer
- Have vaginal bleeding that has not been explained
- Are breastfeeding in the first 6 weeks postpartum (see note)
- Have severe liver disease
There is some concern about women who develop ischemic heart disease, migraines with aura (spots or zig zag lines in vision), or stroke while using progestogen only contraception such as progestogen-only pills (POP), the depo medroxyprogesterone acetate (DMPA) injection, and the implant. However, these concerns are less for the implant and POP and more for DMPA injection.
Note: There have been no studies to provide direct evidence that progestogen only contraception such as the implant has a negative effect on breast milk production or infants. However, because of theoretical concerns about the impact on the development of infants less than 6 weeks of age, the World Health Organization recommends that the implant not be used until after 6 weeks postpartum. The CDC lists breastfeeding under 4 weeks as a category 2 concern in which the benefits outweigh the risks, and cites no risk after 4 weeks postpartum.
A full list of contraindications can be found in the WHO Medical Eligibility Criteria for Contraceptive Use 2009 and the CDC United States Medical Eligibility Criteria for Contraceptive Use 2010
Nexplanon/Implanon consists of a single rod made of ethylene vinylacetate copolymer that is 4 cm long and 2mm in diameter. It is similar to a matchstick in size. The rod contains 68 mg of etonogestrel (sometimes called 3-keto-destrogestrel), a type of progestin. Peak serum etonogestrel concentrations have been found to reach 781–894 pg/mL in the first few weeks, gradually decreasing to 192–261 pg/mL after 1 year, 154–194 pg/mL after 2 years, and 156–177 pg/mL after 3 years, maintaining ovulation suppression and contraceptive efficacy. Serum levels maintain relatively stable through 36 months, which implies that the method may be effective for longer than 3 years.
Insertion and removal
An experienced clinician must perform the insertion of Nexplanon or Implanon to ensure proper insertion and minimize the risk of nerve damage or misplacement, which could result in pregnancy. Before insertion, the arm is washed with a cleaning solution and a local anesthetic is applied to the upper arm around the insertion area. A needle-like applicator is used to insert the rod under the skin into the subdermal tissue on the inner side of the arm between the biceps and triceps muscles. The average time for insertion is 0.5 to 1 minute. A bandage should be kept on the insertion site for 24 hours afterwards. Bruising and mild discomfort are common after insertion. Serious insertion site complications such as infection can occur very rarely, in less than 1% of patients. If a woman receives an implant outside the first five days of her period, she should wait to have sex or use a backup method of contraception (such as a condom, female condom, diaphragm, sponge, or emergency contraception) for the following week after insertion to prevent pregnancy. However, if the implant is inserted during the first five days of a woman's period, she is protected for that cycle and beyond.
Nexplanon and Implanon should be removed after three years; however, they can be removed at any time if pregnancy is desired. The rod must also be removed by an experienced clinician. At removal, a local anesthetic is again used around the implant area at the distal end. If the provider cannot feel the implant, imaging tests may be necessary to locate the rod before it can be removed. A small incision is made in the skin over the end of the implant site. In some cases, a fibrous sheath may have formed around the implant, in which case the sheath must be incised. The implant is removed using forceps. The removal procedure lasts, on average, 3 to 3.5 minutes.
Fertility after removal
Within a week of removal, the hormones from the device leave the body and etonogestrel is undetectable in most users. Most women will begin to ovulate within six weeks of removal. Fertility levels will return to what they were before Nexplanon or Implanon insertion.
Mechanism of action
The mechanism of action of progestin only contraceptives depends on the progestin activity and dose. Intermediate dose progestin-only contraceptives, like Nexplanon or Implanon (and the progestin-only pill Cerazette) allow some follicular development but inhibit ovulation in almost all cycles as the primary mechanism of action. Ovulation was not observed in studies of Implanon in the first two years of use and only rarely in the third year with no pregnancies. A secondary mechanism of action is the progestogenic increase in cervical mucus viscosity which inhibits sperm penetration. Hormonal contraceptives also have effects on the endometrium that theoretically could affect implantation, however no scientific evidence indicates that prevention of implantation actually results from their use.
The possibility of the subdermal contraceptive implant began when silicone was discovered in the 1940s and found to be bio-compatible with the human body. In 1964, Folkman and Long published the first study demonstrating that such a rod could be used to deliver drugs. In 1966 Dziuk and Cook published a study that looked at release rates and suggested that the rods could be well suited for contraception. After a study that used implants with progestogens for contraception, the Population Council developed and patented Norplant and Jadelle. Norplant has six rods and is considered a first generation implant. Jadelle (Norplant II) and other single rod implants that followed were developed because of complications resulting from Norplants 6 rod system. The Jadelle system contains two silicone rods mixed with levonorgestrel. The single rods were less visible under the skin and used etonogestrel as opposed to levonorgestrel in the hopes that it would reduce side effects.
Norplant was used internationally beginning in 1983 and was marketed in the United States and the United Kingdom in 1993. There were many complications associated with Norplant insertion and removal in the United States and it was taken off the market in 2002. Although Jadelle was approved by the FDA, it has never been marketed in the United States, but it is widely used in Africa and Asia. Implanon was first used in Indonesia in 1998 and approved for use in the United States in 2006. Nexplanon was developed to eliminate the problem of non-insertion and localization of Implanon by changing the inserter device and making the rod radiopaque. Nexplanon has replaced Implanon in the UK because of cases of incorrect insertion. As of January 2012, Implanon is no longer being marketed in the US, and Nexplanon is the only available single-rod implant.
- Trussell, James (2011). "Contraceptive efficacy". In Hatcher, Robert A.; Trussell, James; Nelson, Anita L.; Cates, Willard Jr.; Kowal, Deborah; Policar, Michael S. Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 779–863. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734. Table 26–1 =
- Winner, B; Peipert, JF; Zhao, Q; Buckel, C; Madden, T; Allsworth, JE; Secura, GM. (2012), "Effectiveness of Long-Acting Reversible Contraception", New England Journal of Medicine 366 (21): 1998–2007, doi:10.1056/NEJMoa1110855, PMID 22621627
- Mansour, J (2010), "Nexplanon: What Implanon Did Next", J Fam Plann Reprod Health Care 36: 187–189, doi:10.1783/147118910793048629
- Ormsby, Avril (5 Jan 2011). "Contraceptive alert after women fall pregnant". Reuters. Archived from the original on 10 May 2011. Retrieved 10 May 2011.
- Raymond, EG (2011). "Contraceptive Implants". In Hatcher, Robert A.; Nelson, TJ; Guest, F; et al. Contraceptive technology (19th revised ed.). New York: Ardent Media. pp. 144–156.
- Guttmacher (2012). "Contraceptive Use in the United States".
- Kiriwat, O; Patanayindee, A; Koetsawang, S; Korver, T; Bennink, HJ (1999), "A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand", European Journal of Contraction and Reproductive Health Care 4: 85–93
- Funk, Sidney; Funk S, Miller MM, Mishell DR Jr, Archer DF, Poindexter A, Schmidt J, Zampaglione E; Implanon US Study Group (May 2005). "Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel". Contraception 71 (5): 319–26. doi:10.1016/j.contraception.2004.11.007. PMID 15854630. Cite uses deprecated parameter
- Flores, JB; Balderas, ML; Bonilla, MC; Vazquez-Estrada, L (2005), "Clinical Experience and acceptability of the etonogestrel subdermal contraceptive implant", Int J Gynaecol Obstet 90: 228–33, doi:10.1016/j.ijgo.2005.06.007
- Raj, K; Gupta, S; Cotter, S (2004), "Experience with Implanon in a northeast London family planning clinic", Eur J Contracept Reprod Health Care 9: 39–46, doi:10.1080/13625180410001696223
- Booranabunyat, S; Taneepanichskul, S (2004), "Implanon use in Thai women above the age of 35 years", Contraception 69: 489–91, doi:10.1016/j.contraception.2003.12.001
- Zheng, SR; Zheng, HM; Qian, SZ; Sang, GW; Kaper, RF (1999), "A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in health women in China", Eur J Contracept Reprod Health Care 4: 85–93
- Harrison-Woolrych, M; Hill, R (1993), "Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia", Contraception 71: 306–8, doi:10.1016/j.contraception.2004.10.005
- Adams, K and Beal, Margaret (2009), "Implanon: A Review of the Literature With Recommendations for Clinical Management", American College of Nurse-Midwives 54 (2): 142–149, doi:10.1016/j.jmwh.2008.09.004
- Smith, A and Reuter, S (2002), "An assessment of the use of Implanon in three community services", J Fam Plann Reprod Health Care 28: 193–6, doi:10.1783/147118902101196540
- Brache, V; Faundes, A; Alvarez, F; Cochon, L (2002), "Nonmenstural adverse events during use of implantable contraceptives for women: data from clinical trials", Contraception 65: 63–74, doi:10.1016/s0010-7824(01)00289-x
- WHO (2010). "Intrauterine devices (IUDs)". Medical Eligibility Criteria for Contraceptive Use (4th ed.). Geneva: Reproductive Health and Research, WHO. ISBN 978 92 4 1563888.
- Centers for Disease Control and Prevention (2010), United States Medical Eligibility Criteria for Contraceptive Use.
- Biswas A, Viegas OA, Coeling Bennink HJ, Korver T, Ratnam SS (March 2001). "Implanon contraceptive implants: effects on carbohydrate metabolism". Contraception 63 (3): 137–41. doi:10.1016/S0010-7824(01)00182-2. PMID 11368985.
- "Implanon label" (PDF). FDA. 2010-10-26. Retrieved 2010-10-26.
- Makarainen, L; van Beek, A.; Tuomivaara, L; Asplund, B; Bennink, H.C. (1998), "Ovarian function during the use of a single contraceptive implant; Implanon compared with Norplant", Fertil Steril 69: 714–21, doi:10.1016/s0015-0282(98)00015-6
- Hatcher, Robert A (2012). "Dr. Elizabeth Raymond". Contraceptive Technology (20 ed.). Ardent Media Inc. ISBN 978-1597080040. Retrieved 2013-01-22.
- Bahamondes, L; Monteiro-Dantas, C; Espejo-Arce, X; et al. (2006), "A prospective study of the forearm bone density of users of etonogestrel and levonorgestrel-releasing contraceptive implants", Human Reproduction 21: 466–70, doi:10.1093/humrep/dei358
- Wechselberger G, Wolfram D, Pulzl P, Soelder E, Schoeller T (July 2006). "Nerve injury caused by removal of an implantable hormonal contraceptive". Am J Obstet Gynecol 195 (1): 323–6. doi:10.1016/j.ajog.2005.09.016. PMID 16813761.
- Bedsider (2010). "Implant." Retrieved from http://bedsider.org/methods/implant#how_to_tab on March 17, 2011.
- Davies, GC; Feng, LX; Newton, JR; Van Beek, A; Coelingh-Bennink, HJ (1993), "Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel", Contraception 47: 251–61, doi:10.1016/0010-7824(93)90042-6
- Glasier, Anna (2006). "Contraception". In DeGroot, Leslie J.; Jameson, J. Larry (eds.). Endocrinology (5th ed.). Philadelphia: Elsevier Saunders. pp. 3000–1. ISBN 0-7216-0376-9.
- Organon (April 2006). "Implanon SPC (Summary of Product Characteristics)". Retrieved 2007-04-15.
- Rivera R, Yacobson I, Grimes D (1999). "The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices". Am J Obstet Gynecol 181 (5 Pt 1): 1263–9. doi:10.1016/S0002-9378(99)70120-1. PMID 10561657.
- Lapido, OA; Akinso, SA (2005), "Contraceptive implants", Afr J Rerpod Health 9 (1): 16–23
- Folkman, J and Long, DM (1964), "The use of silicon rubber as a carrier for prolonged drug therapy", J Surg res 4: 139–142, doi:10.1016/s0022-4804(64)80040-8
- Dziuk, PJ and Cook, B (1966), "Passage of steroids through silicone rubbers", Endocrinology 78: 208–211, doi:10.1210/endo-78-1-208
- Association of Reproductive Health Professionals (July 2008). "The Single-Rod Contraceptive Implant".